HomeEXECUTIVESDr Ronald Silverman Named BD Chief Medical Officer

Dr Ronald Silverman Named BD Chief Medical Officer

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Ronald (Ron) Silverman, MD, FACS, has been named executive vice president and chief medical officer of BD, effective Dec. 4, 2023.

Dr Ronald Silverman will be responsible for leading the company’s Medical Affairs organization, which includes end-to-end medical affairs across BD’s business units, regions and central team. In this role, he will use medical insights and expertise to advance BD’s pipeline of clinically relevant, innovative solutions that align with evolving patient needs, while also contributing to the safety and compliance of BD’s in-market portfolio of products. He will report to Beth McCombs, executive vice president and chief technology officer for BD, and serve as a member of the BD Executive Leadership Team.

“Ron has been dedicated to advancing care for nearly 30 years, working across clinical practice, academic research and industry roles,” McCombs said. “Ron’s broad expertise and passion for innovation, evidence generation, clinical development, real-world evidence, medical safety, and compliance will help BD build upon our exciting innovation pipeline and promote better outcomes for patients and providers by enabling increasingly efficient, effective and personalized care.”

Dr Ronald Silverman replaces Dr. William Sigmund, who has been chief medical officer for BD since January 2018 and announced his intent to retire from the company in June 2023. Dr. Silverman joins BD from 3M Health Care, where he most recently served as senior vice president and chief medical officer since 2021. He previously led Medical and Clinical Affairs teams for multiple business units within 3M – first for KCI Corporation, followed by Acelity Corporation, and then 3M Health Care Medical Solutions Division. Prior to that, he was chief of plastic surgery at the University of Maryland Medical Center and continues to hold academic appointments at both the University of Maryland and Johns Hopkins schools of medicine.

Dr Ronald Silverman earned a Bachelor of Arts degree and a Doctor of Medicine degree from the University of Maryland and trained in surgery and plastic surgery with Harvard’s Massachusetts General Hospital. He is certified by The American Board of Plastic Surgery, is on the advisory board for the University of Maryland Fischell Department of Bioengineering at the Clark School of Engineering and holds membership with 7 professional organizations. Dr. Silverman holds two patents, has authored more than 80 journal publications and contributed to several textbooks.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

EXECUTIVES ON THE MOVE

Dr Charles R Gordon was the founding Chairman of the Board for Baylor Scott & White's Texas Spine & Joint Hospital. Over the years the hospital has grown, and majority interest of the hospital was sold to Baylor Scott & White and United Surgical Partners International (USPI).
"We are excited to welcome Jeff Anderson to Nutjobs as our new CEO. His broad experience and tactical leadership will be instrumental in executing against our vision to provide innovative, sustainable solutions to our customers," said Paul Kephart, Co-Founder, Chief Technology Officer and Chairperson of the Nutjobs Board.
Potrero Medical believes that this voluntary reorganization will bolster its finances and facilitate its ongoing focus on elevating patient care.
Dr John Parker will work closely with PeriGen's client base to optimize use of the company's analytics for patient care and research. He will also be instrumental in informing product development and regulatory affairs as PeriGen continues to expand its product suite and associated services.
“We’re delighted to welcome Gerald and Hannah to the PrecisionLife team at a time when our deep disease insights and patient stratification biomarkers are finding important new markets and bringing precision approaches to the early, more accurate diagnosis and care of patients with complex chronic diseases,” said Dr Steve Gardner, PrecisionLife CEO.

By using this website you agree to accept Medical Device News Magazine Privacy Policy